These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 18294741

  • 1. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
    Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P.
    Vaccine; 2008 Mar 17; 26(12):1525-9. PubMed ID: 18294741
    [Abstract] [Full Text] [Related]

  • 2. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
    Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A.
    Vaccine; 2006 Apr 12; 24(16):3063-5. PubMed ID: 16464520
    [Abstract] [Full Text] [Related]

  • 3. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.
    Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, Icardi G.
    Vaccine; 2010 Jun 07; 28(25):4123-9. PubMed ID: 20433807
    [Abstract] [Full Text] [Related]

  • 4. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
    Camilloni B, Neri M, Lepri E, Iorio AM.
    Vaccine; 2009 Jun 24; 27(31):4099-103. PubMed ID: 19410623
    [Abstract] [Full Text] [Related]

  • 5. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients.
    de Roux A, Marx A, Burkhardt O, Schweiger B, Borkowski A, Banzhoff A, Pletz MW, Lode H.
    Vaccine; 2006 Mar 06; 24(10):1537-42. PubMed ID: 16288937
    [Abstract] [Full Text] [Related]

  • 6. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.
    Pediatr Infect Dis J; 2009 Jul 06; 28(7):563-71. PubMed ID: 19561422
    [Abstract] [Full Text] [Related]

  • 7. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.
    Sci Transl Med; 2010 Jan 20; 2(15):15ra5. PubMed ID: 20371470
    [Abstract] [Full Text] [Related]

  • 8. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R, Family Medicine Group of Pianiga.
    Vaccine; 2007 May 16; 25(20):3955-61. PubMed ID: 17383057
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
    Frey SE, Reyes MR, Reynales H, Bermal NN, Nicolay U, Narasimhan V, Forleo-Neto E, Arora AK.
    Vaccine; 2014 Sep 03; 32(39):5027-34. PubMed ID: 25045825
    [Abstract] [Full Text] [Related]

  • 10. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M.
    Vaccine; 2009 Oct 23; 27(45):6291-5. PubMed ID: 19840662
    [Abstract] [Full Text] [Related]

  • 11. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J.
    Vaccine; 2008 Jul 04; 26(29-30):3640-6. PubMed ID: 18514980
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
    Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ.
    Clin Vaccine Immunol; 2014 Jul 04; 21(7):989-96. PubMed ID: 24828092
    [Abstract] [Full Text] [Related]

  • 13. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
    Li RC, Fang HH, Li YP, Liu YP, Nong Y, Huang GB.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun 04; 29(6):548-51. PubMed ID: 19040034
    [Abstract] [Full Text] [Related]

  • 14. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G.
    Vaccine; 2012 May 14; 30(23):3470-7. PubMed ID: 22446638
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
    Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB.
    Clin Infect Dis; 2006 Nov 01; 43(9):1135-42. PubMed ID: 17029131
    [Abstract] [Full Text] [Related]

  • 16. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
    de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B.
    Vaccine; 2007 Dec 21; 26(1):119-27. PubMed ID: 18063446
    [Abstract] [Full Text] [Related]

  • 17. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection.
    Ansaldi F, Canepa P, Parodi V, Bacilieri S, Orsi A, Compagnino F, Icardi G, Durando P.
    Vaccine; 2009 May 26; 27(25-26):3345-8. PubMed ID: 19200846
    [Abstract] [Full Text] [Related]

  • 18. Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine.
    Kojimahara N, Maeda A, Kase T, Yamaguchi N.
    Vaccine; 2006 Aug 14; 24(33-34):5966-9. PubMed ID: 16777274
    [Abstract] [Full Text] [Related]

  • 19. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY, Cheong HJ, Noh JY, Seo YB, Choi WS, Cho GJ, Hwang TG, Kim WJ.
    J Med Virol; 2013 Sep 14; 85(9):1591-7. PubMed ID: 23852684
    [Abstract] [Full Text] [Related]

  • 20. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    O'Hagan DT.
    Expert Rev Vaccines; 2007 Oct 14; 6(5):699-710. PubMed ID: 17931151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.